JPS5869813A - 血清脂質低下剤 - Google Patents
血清脂質低下剤Info
- Publication number
- JPS5869813A JPS5869813A JP16872481A JP16872481A JPS5869813A JP S5869813 A JPS5869813 A JP S5869813A JP 16872481 A JP16872481 A JP 16872481A JP 16872481 A JP16872481 A JP 16872481A JP S5869813 A JPS5869813 A JP S5869813A
- Authority
- JP
- Japan
- Prior art keywords
- sulfonic acid
- compound
- formula
- day
- triton
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002966 serum Anatomy 0.000 title claims abstract description 20
- 150000002632 lipids Chemical class 0.000 title abstract description 13
- 230000000994 depressogenic effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000003524 antilipemic agent Substances 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 11
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 235000008975 pantethine Nutrition 0.000 abstract description 8
- 239000011581 pantethine Substances 0.000 abstract description 8
- 229960000903 pantethine Drugs 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 7
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 abstract description 7
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 abstract description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 6
- -1 alkali metal salt Chemical class 0.000 abstract description 5
- 230000003449 preventive effect Effects 0.000 abstract description 5
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 235000019658 bitter taste Nutrition 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 abstract description 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000005516 coenzyme A Substances 0.000 abstract description 2
- 229940093530 coenzyme a Drugs 0.000 abstract description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 240000004371 Panax ginseng Species 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 230000000881 depressing effect Effects 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 230000000741 diarrhetic effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 125000000542 sulfonic acid group Chemical group 0.000 description 2
- MXTPRJXPLFGHEE-UHFFFAOYSA-N 1-amino-2-sulfosulfanylethane Chemical compound NCCSS(O)(=O)=O MXTPRJXPLFGHEE-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 101000906921 Rattus norvegicus N-chimaerin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16872481A JPS5869813A (ja) | 1981-10-23 | 1981-10-23 | 血清脂質低下剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16872481A JPS5869813A (ja) | 1981-10-23 | 1981-10-23 | 血清脂質低下剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5869813A true JPS5869813A (ja) | 1983-04-26 |
| JPH0152366B2 JPH0152366B2 (enrdf_load_stackoverflow) | 1989-11-08 |
Family
ID=15873249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16872481A Granted JPS5869813A (ja) | 1981-10-23 | 1981-10-23 | 血清脂質低下剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5869813A (enrdf_load_stackoverflow) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2517542A1 (fr) * | 1981-12-04 | 1983-06-10 | Sogo Pharm | Medicament pour l'amelioration du metabolisme lipidique |
| JPS58167511A (ja) * | 1982-03-30 | 1983-10-03 | Sogo Yatsukou Kk | 血清脂質代謝改善並びに動脈硬化防止剤 |
| WO2002047682A1 (fr) * | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Composition ameliorant les lipides sanguins |
| WO2002047683A1 (fr) * | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Composition ameliorant les lipides dans le sang |
| WO2002049640A1 (fr) * | 2000-12-18 | 2002-06-27 | Sankyo Company, Limited | Composition servant a faire baisser le taux de triglycerides |
| US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
| US6998422B2 (en) | 2000-11-07 | 2006-02-14 | Sankyo Company, Limited | Lipid peroxide-lowering compositions |
| US7037934B2 (en) | 2000-12-14 | 2006-05-02 | Sankyo Company, Limited | Blood lipid ameliorant composition |
-
1981
- 1981-10-23 JP JP16872481A patent/JPS5869813A/ja active Granted
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2517542A1 (fr) * | 1981-12-04 | 1983-06-10 | Sogo Pharm | Medicament pour l'amelioration du metabolisme lipidique |
| JPS58167511A (ja) * | 1982-03-30 | 1983-10-03 | Sogo Yatsukou Kk | 血清脂質代謝改善並びに動脈硬化防止剤 |
| US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
| US6998422B2 (en) | 2000-11-07 | 2006-02-14 | Sankyo Company, Limited | Lipid peroxide-lowering compositions |
| WO2002047682A1 (fr) * | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Composition ameliorant les lipides sanguins |
| WO2002047683A1 (fr) * | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Composition ameliorant les lipides dans le sang |
| US7012067B2 (en) | 2000-12-14 | 2006-03-14 | Sankyo Company, Limited | Blood lipid ameliorant composition |
| US7037934B2 (en) | 2000-12-14 | 2006-05-02 | Sankyo Company, Limited | Blood lipid ameliorant composition |
| WO2002049640A1 (fr) * | 2000-12-18 | 2002-06-27 | Sankyo Company, Limited | Composition servant a faire baisser le taux de triglycerides |
| CN1307990C (zh) * | 2000-12-18 | 2007-04-04 | 三共株式会社 | 甘油三酸酯降低剂组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0152366B2 (enrdf_load_stackoverflow) | 1989-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3781429A (en) | Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents | |
| JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
| US4234601A (en) | Analgesic potentiation | |
| JPS5869813A (ja) | 血清脂質低下剤 | |
| CA1291043C (en) | Composition and method for reducing acetaldehyde toxicity | |
| US4233316A (en) | Analgesic potentiation | |
| EP0012621B1 (en) | Analgesic composition comprising acetaminophen as a potentiating agent | |
| EP0085544A1 (en) | The use of aralkanoic acids and esters for the treatment of myelogenous leukemia | |
| EP0055593B1 (en) | Compositions comprising e-prostaglandins | |
| JPH04287660A (ja) | フッ素症を予防する組成物とその方法 | |
| US3157574A (en) | Method of reducing cholesterol levels | |
| US4568683A (en) | Lipid metabolism with pantetheine-S-sulfonic acid | |
| US3501577A (en) | Method of treating hypertension with alkali metal salts of zinc diethylenetriaminepentaacetate | |
| JP2548223B2 (ja) | 腎臓疾患治療剤 | |
| JPS58167511A (ja) | 血清脂質代謝改善並びに動脈硬化防止剤 | |
| JP2545321B2 (ja) | 平滑筋収縮抑制剤 | |
| JPH06102624B2 (ja) | 非心臓由来の不整脈防止薬 | |
| JPS5962523A (ja) | 抗腫瘍剤 | |
| US3749781A (en) | Pharmaceutical composition and method of treatment | |
| US11413273B2 (en) | Prophylactic or therapeutic agent for pulmonary hypertension comprising unsaturated 5-membered heterocycle-containing compound | |
| JPS63267727A (ja) | Ｓ−ラクトイルグルタチオンおよび／またはその塩を有効成分とする医薬 | |
| JPS61158970A (ja) | ピラジンジアゾヒドロキシド化合物 | |
| JPS63215628A (ja) | グリオキサラ−ゼｉ阻害剤 | |
| US3755567A (en) | Method for treating alcoholism | |
| JPS64923B2 (enrdf_load_stackoverflow) |